Panel discussion on November 9 at Wonderland: Miami will review the benefits of ketamine treatment for depression and other mental…
Category: Braxia Scientific
Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base
Revenue from four Canadian clinics increased 80.3% to $407,075 year-over-year Exceeding monthly IV Ketamine infusion targets, ramping up…
Braxia Scientific to Commence Landmark Clinical Trial to Conduct Canada’s First Multiple-Dose Psilocybin Clinical Trial for Treatment Resistant Depression
First multiple-dose psilocybin clinical trial will be conducted at Braxia Health’s Canadian Rapid Treatment Centers Trial…
Braxia Scientific Provides Corporate Update and Reports Fiscal Fourth Quarter and Full-Year 2021 Financial Results
TORONTO, July 30, 2021 /CNW/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496),…
Braxia Scientific CEO, Chief Medical Officer Awarded $918,000 by Canadian Government to Study Benefits of Integrating Ketamine with Cognitive Behavioural Therapy to Reduce Suicidality
Innovative Ketamine clinical trial ranked in the 94th percentile by the CIHR peer review committee Suicidality…
Braxia Scientific Secures Approval for Direct Billing Insurance on Ketamine Treatments for Veterans Affairs Canada Clients
TORONTO, July 20, 2021 /CNW Telbec/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF)…
Braxia Scientific to Discuss Psychiatric Treatment Discovery and Development with Oxford University Researchers at AIMday Experimental Medicine in Psychiatry on July 7, 2021
TORONTO, July 7, 2021 /CNW/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496),…
Braxia Scientific Launches Psilocybin-Assisted Clinical Therapy Training Program to Develop New Generation of Qualified Physicians, Psychotherapists and Psychologists for Mental Health
TORONTO, June 29, 2021 /CNW/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB:…
Braxia Scientific Awarded Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar Depression
Fully funded by the Canadian Institute of Health Research (CIHR), this multi-site clinical trial will take…
American Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger Mcintyre
International Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for…
Braxia Scientific Appoints Dr. David Greenberg to Board of Directors
TORONTO, May 31, 2021 /CNW Telbec/ – Braxia Scientific Corp. (the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496),…
Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia’s Symposium on Rapid Acting Anti-Depressants
Over 200 physicians and healthcare providers from Canada, U.S., and Asia to attend Braxia’s Symposium on rapid acting anti-depressants…